Listerine with fluoride meeting postponed
This article was originally published in The Rose Sheet
Executive Summary
"Feedback" meeting on OTC anticaries drug products monograph slated for June 18 in Rockville, MD will be rescheduled, probably within a month, according to FDA's division of OTC Drug Products. Meeting is part of Pfizer's efforts to amend the monograph to allow a mouthrinse combining essential oils and sodium fluoride (1'The Rose Sheet" June 10, 2002, p. 5). FDA says it needs more time to review relevant materials...
You may also be interested in...
Listerine With Fluoride Development Continues With “Feedback” Meeting
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.